Transistion from manual to femto keratoplasty

Article

A commitment to predictability and safety

The introduction of femtosecond laser technology in the ophthalmologic practice has given rise to significant advances in a great variety of corneal surgical procedures, especially in terms of predictability and safety. This technology, based on the use of a solid state laser (Nd:Glass) beam of a wavelength of 1040–1060 nm, is able to induce a photodisruption of the corneal tissue at a specific plane without thermal or shockwave damage to the surrounding tissue, and with a extremely high level of precision. Specifically, femtosecond lasers form a series of microbubbles (3–12 µm) of carbon dioxide and water vapour due to the photodisruption induced at the programmed depth. These microbubbles interconnect generating a dissection plane. This capability of femtosecond laser technology of precisely programming and generating different types of corneal tissue dissections makes it a valuable tool for keratoplasty.

A valuable tool

Another significant advantage of femto keratoplasty is the possibility of customizing the corneal trephination according to an established pattern. As presented at Femto Keratoplasty Forum 2012 by Dr Thomas Neuhann, it is highly recommended to use dissections with an internal diameter smaller than the external and slanted inwards to promote good self healing.7 This can easily be achieved with the zigzag, tongue in groove ('barrel'), and 'square-zag' shapes.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.